Apolipoprotein A-1 (Apo-A) Test
The Apo-A1 test measures serum apolipoprotein A-1, the principal structural protein of HDL particles and a quantitative marker of reverse cholesterol transport capacity. It provides particle-based cardiovascular risk assessment that complements HDL cholesterol, especially when HDL mass is altered by particle-size variation, and the Apo-B:Apo-A1 ratio integrates atherogenic and atheroprotective…
1
Biomarkers
Blood (serum)
Sample
3–5 business days
Turnaround
Preferred (12 hours)
Fasting
What is the Apo-A1 test?
The Apolipoprotein A-1 Test measures the serum concentration of the major structural protein of high-density lipoprotein, offering a particle-based assessment of HDL-mediated reverse cholesterol transport that complements and sometimes supersedes HDL cholesterol. Practitioners order it to refine cardiovascular risk stratification when HDL cholesterol is discordant with clinical expectation, to assess residual risk in patients with metabolic syndrome or controlled LDL, and to guide lipid-lowering therapy in those with low HDL or mixed dyslipidaemia. Apo-A1 is particularly valuable when HDL mass is altered by factors that change particle size without proportional changes in particle number — for example, hypertriglyceridaemia produces small, cholesterol-depleted HDL, so HDL cholesterol falls while Apo-A1 may be preserved, reflecting the true particle count. The Apo-B:Apo-A1 ratio integrates both atherogenic and atheroprotective burdens and has been shown to predict cardiovascular events as robustly as non-HDL or LDL cholesterol, making the pair a useful adjunct to the standard lipid panel.
What does the Apo-A1 test measure?
Apolipoprotein A-1 is the principal structural protein of high-density lipoprotein particles, comprising roughly 70% of HDL protein mass. It is synthesised by the liver and intestine and serves as the essential scaffold upon which nascent HDL is assembled. Apo-A1 activates lecithin-cholesterol acyltransferase, the enzyme that esterifies free cholesterol on the HDL surface, enabling reverse cholesterol transport from peripheral tissues to the liver. Its plasma concentration reflects both the number and size distribution of HDL particles, making it a functional measure of HDL-mediated atheroprotection that is independent of cholesterol content.
Apo-A1 is a quantitative index of HDL particle number and a marker of reverse cholesterol transport capacity. Because HDL cholesterol mass can be misleading when particle size varies, Apo-A1 often provides more precise cardiovascular risk stratification. Epidemiological data link low Apo-A1 to increased coronary risk, independent of LDL cholesterol, and low values are a feature of metabolic syndrome and insulin resistance. The ratio of apolipoprotein B to apolipoprotein A-1 integrates atherogenic and atheroprotective particle burdens into a single metric that performs as well or better than conventional lipid ratios.
Why is the Apo-A1 test ordered?
- Cardiovascular risk stratification in patients with metabolic syndrome, insulin resistance, or type 2 diabetes, where HDL cholesterol may underestimate atheroprotective capacity
- Evaluation of low HDL cholesterol to distinguish true HDL particle deficiency from cholesterol-depleted but numerically adequate particles seen in hypertriglyceridaemia
- Assessment of residual cardiovascular risk in patients with well-controlled LDL cholesterol but persistent clinical concerns or family history
- Familial combined hypoalphalipoproteinaemia or suspected genetic HDL disorders, interpreted with family history and HDL cholesterol
- Calculation of the apolipoprotein B:apolipoprotein A-1 ratio, a robust integrative measure of cardiovascular risk that performs as well as or better than conventional ratios
- Monitoring response to lifestyle intervention, lipid-modifying therapy, or investigational HDL-targeted treatments in selected patients
- Evaluation of dyslipidaemia in chronic kidney disease, where HDL cholesterol and Apo-A1 may dissociate
Sample collection and turnaround
Sample type
Blood (serum)
Fasting required
Preferred (12 hours)
Collection method
Venipuncture at patient service centre
Turnaround
3–5 business days
Collection notes
Phlebotomy required; fasting for 12 hours is preferred to standardise triglyceride-dependent HDL remodelling, though some laboratories accept non-fasting samples. Avoid the acute-phase window after illness, surgery, or myocardial infarction. Separate serum promptly and store refrigerated or frozen if analysis is delayed.
Specimen requirements
Minimum 0.5 mL serum; gel separator acceptable. Apo-A1 is stable refrigerated for several days and frozen for months. Note that Access Medical Laboratories is the processing laboratory; confirm specimen-handling requirements and reference intervals with the lab.
What can affect Apo-A1 results?
Apo-A1 behaves as a negative acute-phase reactant, falling during acute illness, surgery, or myocardial infarction; defer testing until recovery or interpret with high-sensitivity CRP to identify an acute phase.
Metabolic syndrome and visceral adiposity lower both Apo-A1 and HDL particle number through mechanisms that include increased hepatic lipase activity and reduced Apo-A1 synthesis.
Moderate alcohol intake raises both HDL cholesterol and Apo-A1, an effect that partly explains the epidemiological association between moderate drinking and lower coronary risk.
Exogenous oestrogen increases hepatic synthesis of Apo-A1 and raises HDL cholesterol; the route of administration (oral vs transdermal) influences the magnitude.
Statins modestly increase Apo-A1, while fibrates raise it more substantially; niacin also increases Apo-A1, though its clinical use has declined after recent outcome-trial disappointments.
Smoking lowers both HDL cholesterol and Apo-A1, contributing to its atherogenic effect; smoking cessation reverses the deficit over weeks to months.
What do Apo-A1 results mean?
Elevated
Elevated Apo-A1 is generally favourable and associated with lower cardiovascular risk. Marked elevations can occur with oestrogen therapy, moderate alcohol use, or genetic variants such as cholesteryl ester transfer protein (CETP) deficiency, which produce large, cholesterol-rich HDL but whose cardiovascular protection is contested. Very high Apo-A1 alone does not require intervention.
Normal
A normal Apo-A1 indicates adequate HDL particle number and typical reverse cholesterol transport capacity. Interpret with the lipid panel and the Apo-B:Apo-A1 ratio; normal Apo-A1 with elevated Apo-B still confers net atherogenic risk.
Reduced
Low Apo-A1 reflects reduced HDL particle number and impaired reverse cholesterol transport. Causes include metabolic syndrome, insulin resistance, obesity, smoking, genetic hypoalphalipoproteinaemias, and chronic kidney disease. Low values independently predict coronary risk, and when both Apo-A1 and HDL cholesterol are low, particle deficiency is confirmed. Discordance — low HDL cholesterol with preserved Apo-A1 — occurs in hypertriglyceridaemia, where cholesterol-depleted small HDL particles are present in normal numbers.
Note: Apo-A1 must be interpreted alongside HDL cholesterol, apolipoprotein B, and triglycerides to fully assess lipoprotein-mediated risk. Reference limits differ by sex, age, and assay platform. An acute-phase state can spuriously lower Apo-A1, so pair with CRP or defer until recovery. The Apo-B:Apo-A1 ratio integrates both sides of lipoprotein risk and is more informative than either apolipoprotein alone.
Frequently asked questions
Apo-A1 measures the number of HDL particles by quantifying the protein that scaffolds each particle, while HDL cholesterol measures the cholesterol mass carried by those particles. When particles are small and cholesterol-depleted — as in hypertriglyceridaemia — HDL cholesterol falls while Apo-A1 may remain normal, making Apo-A1 a more accurate reflection of HDL particle number.
How to access the Apo-A1 test
The Apo-A1 reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.
Create Free AccountAbout this page
Published: October 7, 2026
Last reviewed: October 7, 2026
- Grundy SM, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. Circulation. (2019)
- Sniderman AD, et al. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiol. (2019)
- Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy — a review of the evidence. J Intern Med. (2006)
- Mora S, et al. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation. (2009)
- Rader DJ, Hovingh GK. HDL and cardiovascular disease. Lancet. (2014)
This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.
Related tests
cardiovascular
Apo-B
The Apo-B test measures serum apolipoprotein B, the structural protein present as a single copy on each atherogenic lipoprotein particle (VLDL, IDL, LDL, Lp(a)). It directly enumerates particle number, correlating more strongly with cardiovascular risk than LDL-cholesterol, and is especially informative in metabolic syndrome, diabetes, and hypertriglyceridaemia where small dense LDL predominates.
cardiovascular
Lipid Panel
The Lipid Panel measures total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, non-HDL cholesterol, and VLDL cholesterol from a single fasting serum specimen, providing the foundational cardiovascular lipid risk profile for ASCVD risk stratification, lipid-lowering therapy initiation and monitoring, familial hypercholesterolaemia identification, and atherogenic dyslipidaemia…
cardiovascular
HDL-C
The HDL cholesterol test measures the cholesterol carried within high-density lipoprotein particles, a core component of the lipid profile and cardiovascular risk assessment. Low HDL-C is an independent risk marker, but HDL-C reflects cholesterol concentration rather than HDL function and is a risk marker, not a validated treatment target;